Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC	Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm	Recruiting	Phase 1 / Phase 2	2026-09-08		NCT07718243

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Faron Pharmaceuticals Ltd	4
Institute of Cancer Research, United Kingdom	59
Royal Marsden NHS Foundation Trust	89
The Christie NHS Foundation Trust	35

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Christie NHS Foundation Trust	Manchester	United Kingdom	113
The Royal Marsden NHS Foundation Trust - Drug Development Unit	Sutton	United Kingdom	2